Traders Buy High Volume of Wave Life Sciences Call Options (NASDAQ:WVE)

Wave Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) was the target of unusually large options trading on Wednesday. Traders bought 2,253 call options on the stock. This represents an increase of approximately 533% compared to the average daily volume of 356 call options.

Insider Buying and Selling

In other Wave Life Sciences news, CFO Kyle Moran sold 17,146 shares of the stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $9.00, for a total transaction of $154,314.00. Following the completion of the transaction, the chief financial officer now directly owns 19,777 shares in the company, valued at $177,993. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Kyle Moran sold 17,146 shares of the firm's stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total transaction of $154,314.00. Following the completion of the sale, the chief financial officer now owns 19,777 shares of the company's stock, valued at approximately $177,993. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Paul Bolno sold 48,366 shares of the business's stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total value of $279,555.48. Following the completion of the transaction, the chief executive officer now directly owns 359,059 shares in the company, valued at $2,075,361.02. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Wave Life Sciences

A number of large investors have recently bought and sold shares of the company. Artal Group S.A. increased its stake in Wave Life Sciences by 34.7% in the 1st quarter. Artal Group S.A. now owns 4,051,400 shares of the company's stock valued at $24,997,000 after buying an additional 1,044,000 shares during the last quarter. Emerald Advisers LLC bought a new stake in Wave Life Sciences during the second quarter worth about $12,441,000. Price T Rowe Associates Inc. MD raised its holdings in Wave Life Sciences by 14.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,861,254 shares of the company's stock worth $11,485,000 after acquiring an additional 233,891 shares in the last quarter. Vanguard Group Inc. boosted its position in Wave Life Sciences by 39.7% during the first quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company's stock valued at $11,316,000 after purchasing an additional 521,665 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new position in Wave Life Sciences in the second quarter valued at approximately $9,086,000. Institutional investors and hedge funds own 89.73% of the company's stock.

Analyst Ratings Changes

WVE has been the subject of several research reports. Mizuho restated an "outperform" rating and issued a $19.00 price objective on shares of Wave Life Sciences in a research report on Tuesday, June 25th. B. Riley boosted their price objective on shares of Wave Life Sciences from $11.00 to $19.00 and gave the stock a "buy" rating in a research report on Thursday, October 3rd. Leerink Partners increased their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday. HC Wainwright upped their price target on Wave Life Sciences from $15.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. Finally, JPMorgan Chase & Co. began coverage on shares of Wave Life Sciences in a report on Friday, September 27th. They issued an "overweight" rating and a $13.00 price objective on the stock. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Wave Life Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $18.11.

Wave Life Sciences Stock Up 75.0 %

Wave Life Sciences stock traded up $6.42 during mid-day trading on Wednesday, hitting $14.98. 16,199,194 shares of the company's stock were exchanged, compared to its average volume of 1,062,126. Wave Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $15.54. The firm has a market capitalization of $1.87 billion, a P/E ratio of -26.30 and a beta of -1.10. The company's 50 day simple moving average is $6.54 and its 200-day simple moving average is $6.04.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.09). The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $24.80 million. Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. During the same quarter in the previous year, the business earned ($0.20) earnings per share. Research analysts expect that Wave Life Sciences will post -1.02 EPS for the current year.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.